Clinical Trial Update: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants [Phase 1]

View source ↗

Summary

This Phase 1 AstraZeneca trial evaluates how multiple oral doses of AZD2389 alter the pharmacokinetics of midazolam, caffeine, and bupropion in healthy particip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• AZD2389
• Caffeine (caffeine)
• Midazolam (Midazolam)
• bupropion (bupropion)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Chronic Liver Disease, Healthy Participants | Phase 1 | Status: COMPLETED